|
|

|
|
MVA (Modified Vaccinia Ankara)
Together with Acambis, Baxter is developing a third generation smallpox vaccine based on the strain Modified Vaccinia Ankara (MVA). MVA is an attenuated form of the current generation of smallpox vaccines and, as such, is expected to allow the safe inoculation of “at risk” individuals with weakened immune systems, who could otherwise not be vaccinated against smallpox.
» Printversion
|
|
|

|
Baxter initiates clinical study with cell-based candidate H5N1 Pandemic Vaccine
» read more
Baxter to participate in development of cell-based vaccines for U.S. Department of Health and Human Services
» read more
Baxter Receives Contract From National Health Service in United Kingdom to Produce Stockpile of H5N1 Flu Vaccine
» read more
|
|